Oliceridine yielded clinically meaningful pain relief vs placebo after bunionectomy

NEW ORLEANS — Use of oliceridine following bunionectomy yielded clinically meaningful pain relief compared with placebo, according to results presented at the American Academy of Orthopaedic Surgeons Annual Meeting.

Peter G. Whang , MD, and colleagues randomly assigned patients who underwent bunionectomy to receive placebo (n=79), oliceridine regimen A (1.5-mg loading, 0.1-mg demand; n=76), oliceridine regimen B (1.5-mg loading, 0.35-mg demand; n=79), oliceridine regimen C (1.5-mg loading, 0.5 mg-demand; n=79) or morphine (n=76). Researchers collected pain intensity scores at various time points and noted adverse events during hospitalization, as well as during the 7-day postoperative period.

Peter G. Whang

“A treatment responder was defined as a patient who achieved 30% improvement in time-weighted sum of pain intensity difference from baseline and 48 hours. They did not receive any rescue pain medications, did not discontinue the study early and did not reach the dosing limit corresponding to the limit within the first 12 hours,” Whang said.

The oliceridine groups had a significantly greater rate of treatment responders vs. the placebo group, according to Whang. Similarly, when patients were subdivided into quartiles based on cumulative oliceridine exposure, results showed a greater percentage of treatment responders in the oliceridine groups.

“Few patients across all quartiles required discontinued treatment due to adverse events,” Whang said. – by Casey Tingle

Reference:

Whang PG, et al. Paper #232. Presented at: American Academy of Orthopaedic Surgeons Annual Meeting; March 6-10, 2018; New Orleans,

Disclosure: Whang reports he is a consultant for Trevena.